A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes

Gynecologic Oncology

Volumn 141, Issue 2, 2016, Pages 240-246

  Mabuchi, Seiji ^a   Isohashi, Fumiaki ^a   Yokoi, Takeshi ^b   Takemura, Masahiko ^c   Yoshino, Kiyoshi ^a   Shiki, Yasuhiko ^d   Ito, Kimihiko ^e   Enomoto, Takayuki ^f   Ogawa, Kazuhiko ^b   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kaizuka City Hospital   (Japan)

^c OSAKA GENERAL MEDICAL CENTER   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

^e OSAKA ROSAI HOSPITAL   (Japan)

^f NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Carboplatin; Cervical cancer; Consolidation chemotherapy; IMRT; Paclitaxel; Phase II study

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LEUKOPENIA; LYMPHEDEMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PELVIS LYMPH NODE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE CERVIX CANCER; ADJUVANT CHEMORADIOTHERAPY; CLINICAL TRIAL; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE CARE; PROCEDURES; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMORADIOTHERAPY, ADJUVANT; CONSOLIDATION CHEMOTHERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PACLITAXEL; POSTOPERATIVE CARE; RADIOTHERAPY, INTENSITY-MODULATED; UTERINE CERVICAL NEOPLASMS;

EID: 84958568813     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.02.011     Document Type: Article

References (40)

1. B.J. Monk, D.S. Cha, J.L. Walker, R.A. Burger, N.S. Ramsinghani, A. Manetta, P.J. DiSaia, and M.L. Berman Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma Gynecol. Oncol. 54 1994 4 9
2. N. Sakuragi, C. Satoh, N. Takeda, H. Hareyama, M. Takeda, R. Yamamoto, T. Fujimoto, M. Oikawa, T. Fujino, and S. Fujimoto Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy Cancer 85 1999 1547 1554
3. M. Hosaka, H. Watari, T. Mitamura, Y. Konno, T. Odagiri, T. Kato, M. Takeda, and N. Sakuragi Survival and prognosticators of node-positive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy Int. J. Clin. Oncol. 16 2011 33 38
4. W.A. Peters III, P.Y. Liu, R.J. Barrett II, R.J. Stock, B.J. Monk, J.S. Berek, L. Souhami, P. Grigsby, W. Gordon Jr., and D.S. Alberts Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix J. Clin. Oncol. 18 2000 1606 1613
5. F. Petrelli, A. De Stefani, F. Raspagliesi, D. Lorusso, and S. Barni Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis Gynecol. Oncol. 134 2014 166 171
6. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials J. Clin. Oncol. 26 2008 5802 5812
7. NCT01755845. Clinical Trials.gov. A Service of the U.S. National Institute of Health. http://www.clinicaltrials.gov (Accessed December 1, 2015).
8. NCT01414608. Clinical Trials.gov. A Service of the U.S. National Institute of Health. http://www.clinicaltrials.gov (Accessed December 1, 2015).
9. R. Kitagawa, N. Katsumata, T. Shibata, T. Kamura, T. Kasamatsu, T. Nakanishi, S. Nishimura, K. Ushijima, M. Takano, T. Satoh, and H. Yoshikawa Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: The open-label randomized phase III trial JCOG0505 J. Clin. Oncol. 33 2015 2129 2135
10. L.X. Yang, E.B. Douple, J.A. O'Hara, and H.J. Wang Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism for radiopotentiation Radiat. Res. 143 1995 309 315
11. R.B. Tishler, C.R. Geard, E.J. Hall, and P.B. Schiff Taxol sensitizes human astrocytoma cells to radiation Cancer Res. 52 1992 3495 3497
12. K. Bergmark, E. Avall-Lundqvist, P.W. Dickman, L. Henningsohn, and G. Steineck Lymphedema and bladder-emptying difficulties after radical hysterectomy for early cervical cancer and among population controls Int. J. Gynecol. Cancer 16 2006 1130 1139
13. G.G. Kenter, A.C. Ansink, A.P. Heintz, E.J. Aartsen, J.F. Delemarre, and A.A. Hart Carcinoma of the uterine cervix stage I and IIA: results of surgical treatment: complications, recurrence and survival Eur. J. Surg. Oncol. 15 1989 55 60
14. S. Mabuchi, M. Okazawa, F. Isohashi, K. Matsuo, Y. Ohta, O. Suzuki, Y. Yoshioka, T. Enomoto, S. Kamiura, and T. Kimura Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer Gynecol. Oncol. 123 2011 241 247
15. H. Hareyama, K. Hada, K. Goto, S. Watanabe, M. Hakoyama, K. Oku, Y. Hayakashi, E. Hirayama, and K. Okuyama Prevalence, classification, and risk factors for postoperative lower extremity lymphedema in women with gynecologic malignancies: a retrospective study Int. J. Gynecol. Cancer 25 2015 751 757
16. J.M. Galvin, and W. De Neve Intensity modulating and other radiation therapy devices for dose painting J. Clin. Oncol. 25 2007 924 930
17. S. Mabuchi, R. Takahashi, F. Isohashi, T. Yokoi, K. Ito, T. Tsutui, T. Ogata, Y. Yoshioka, K. Ogawa, and T. Kimura A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes Int. J. Gynecol. Cancer 23 2013 1279 1286
18. M. Okazawa, S. Mabuchi, F. Isohashi, O. Suzuki, Y. Ohta, M. Fujita, K. Yoshino, T. Enomoto, S. Kamiura, and T. Kimura The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy Int. J. Gynecol. Cancer 22 2012 490 497
19. F. Isohashi, S. Mabuchi, Y. Yoshioka, Y. Seo, O. Suzuki, K. Tamari, M. Yamashita, H. Unno, Y. Kinose, K. Kozasa, I. Sumida, Y. Otani, T. Kimura, and K. Ogawa Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume histogram parameters Radiat. Oncol. 10 2015 180
20. W. Small Jr., L.K. Mell, P. Anderson, C. Creutzberg, J. De Los Santos, D. Gaffney, A. Jhingran, L. Portelance, T. Schefter, R. Iyer, M. Varia, K. Winter, and A.J. Mundt Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer Int. J. Radiat. Oncol. Biol. Phys. 71 2008 428 434
21. Japan Clinical Oncology Group, T. Toita, T. Ohno, Y. Kaneyasu, T. Uno, R. Yoshimura, T. Kodaira, K. Furutani, G. Kasuya, S. Ishikura, T. Kamura, and M. Hiraoka A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer Jpn. J. Clin. Oncol. 40 2010 456 463
22. T. Hisamatsu, S. Mabuchi, K. Yoshino, M. Fujita, T. Enomoto, T. Hamasaki, and T. Kimura Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer Int. J. Gynecol. Cancer 22 2012 623 629
23. S. Mabuchi, K. Morishige, T. Enomoto, and T. Kimura Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature J. Gynecol. Oncol. 21 2010 93 96
24. S. Mabuchi, K. Morishige, M. Fujita, T. Tsutsui, M. Sakata, T. Enomoto, and T. Kimura The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy Gynecol. Oncol. 113 2009 200 204
25. J.D. Cox, J. Stetz, and T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for research and treatment of cancer (EORTC) Int. J. Radiat. Oncol. Biol. Phys. 31 1995 1341 1346
26. S. Mabuchi, F. Isohashi, S. Maruoka, T. Hisamatsu, T. Takiuchi, Y. Yoshioka, and T. Kimura Post-treatment follow-up procedures in cervical cancer patients previously treated with radiotherapy Arch. Gynecol. Obstet. 286 2012 179 185
27. S. Mabuchi, F. Isohashi, Y. Yoshioka, K. Temma, T. Takeda, T. Yamamoto, T. Enomoto, K. Morishige, T. Inoue, and T. Kimura Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy Int. J. Gynecol. Cancer 20 2010 834 840
28. S. Mabuchi, M. Okazawa, F. Isohashi, Y. Ohta, S. Maruoka, Y. Yoshioka, and et al. Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic lymph node metastases Gynecol. Oncol. 120 2011 94 100
29. M. Okazawa, S. Mabuchi, F. Isohashi, O. Suzuki, Y. Yoshioka, T. Sasano, Y. Ohta, S. Kamiura, K. Ogawa, and T. Kimura Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience Int. J. Gynecol. Cancer 23 2013 567 575
30. S. Mabuchi, K. Morishige, F. Isohashi, Y. Yoshioka, T. Takeda, T. Yamamoto, and et al. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors Gynecol. Oncol. 115 2009 482 487
31. A. Dueñas-González, J.J. Zarbá, F. Patel, J.C. Alcedo, S. Beslija, L. Casanova, P. Pattaranutaporn, S. Hameed, J.M. Blair, H. Barraclough, and M. Orlando Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix J. Clin. Oncol. 29 2011 1678 1685
32. C.C. Wang, H.H. Chou, L.Y. Yang, H. Lin, W.S. Liou, C.W. Tseng, F.Y. Liu, J.D. Liou, K.G. Huang, H.J. Huang, E.Y. Huang, C.H. Chen, T.C. Chang, C.J. Chang, J.H. Hong, and C.H. Lai A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: an Asian Gynecologic Oncology Group study Gynecol. Oncol. 137 2015 462 467
33. P.G. Rose, K. Degeest, S. McMeekin, and N. Fusco A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 107 2007 274 279
34. K. Kim, E.K. Chie, H.G. Wu, S.W. Ha, J.S. Kim, I.A. Kim, and H.P. Lee Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer Gynecol. Oncol. 101 2006 398 402
35. H.N. Lee, K.H. Lee, D.W. Lee, Y.S. Lee, E.K. Park, and J.S. Park Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer Int. J. Gynecol. Cancer 21 2011 128 136
36. H.S. Kim, M.K. Kim, H.J. Kim, S.S. Han, and J.W. Kim Phase II study of consolidation chemotherapy after adjuvant or primary concurrent chemoradiation using paclitaxel and carboplatin to treat high-risk early-stage or locally advanced cervical cancer Cancer Res. Treat. 44 2012 97 103
37. T.S. Lee, S.B. Kang, Y.T. Kim, B.J. Park, Y.M. Kim, J.M. Lee, S.M. Kim, Y.T. Kim, J.H. Kim, and K.T. Kim Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study Int. J. Radiat. Oncol. Biol. Phys. 86 2013 304 310
38. F.Y. de Vos, A.M. Bos, J.A. Gietema, E. Pras, A.G. Van der Zee, E.G. de Vries, and P.H. Willemse Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer Anticancer Res. 24 2004 345 348
39. D. Addeo, S. Blank, F. Muggia, and S. Formenti Concurrent radiotherapy, paclitaxel and dose escalating carboplatin in the treatment of cervical cancer - a phase I study Anticancer Res. 28 2008 3143 3146
40. NCT00980954. Clinical Trials.gov. A Service of the U.S. National Institute of Health. http://www.clinicaltrials.gov (Accessed December 1, 2015).